Therapeutic use of the retinoblastoma susceptibility gene product
AssigneesThe Regents of the University of California, Canji, Inc.
InventorsWen-Hwa Lee, Eva Y-H.P. Lee, David W. Goodrich, H. Michael Shepard, Nan Ping Wang, Duane Johnson
Life of this patent
Estimating the term…
Abstract
This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the cell with an effective amount of retinoblastoma protein or polypeptide. This method also is useful to prevent or treat retinoblastoma or a secondary cancer to retinoblastoma by administering to a patient a functional retinoblastoma protein or polypeptide.
Claims24
A method of treating pathologically proliferating cells lacking endogenous functional retinoblastoma protein, the method comprising contacting the proliferating cells with an effective amount of a retinoblastoma polypeptide comprising a C-terminal retinoblastoma polypeptide, the polypeptide having a molecular weight of about 56 kD, whereby cellular proliferation is inhibited.
A method of treating pathologically proliferating cells lacking endogenous functional retinoblastoma protein, the method comprising contacting the proliferating cells with an effective amount of a C-terminal retinoblastoma polypeptide having a molecular weight of about 56 kD, whereby cellular proliferation is inhibited.
A pharmaceutical composition comprising a therapeutically effective amount of a retinoblastoma polypeptide and a pharmacologically suitable carrier, wherein the retinoblastoma polypeptide comprises a C-terminal retinoblastoma polypeptide, the polypeptide having a molecular weight of about 56 kD.
A pharmaceutical composition comprising a therapeutically effective amount of a C-terminal retinoblastoma polypeptide having a molecular weight of about 56 kD and a pharmacologically suitable carrier.
Dependencies are inferred from the claim text.